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Background: Twenty-four-hour and nighttime blood pressure (BP) levels are more
strongly associated with cardiovascular risk than office or daytime BP measurements.
However, it remains undocumented which of the office and ambulatory BP
measurements have the strongest association and predictive information in relation to
the presence of type I, or arteriolosclerosis type, cerebral small vessel diseases (CSVD).
Methods:
A subset of 429 participants from the Maracaibo Aging Study
[aged ≥40 years (women, 73.7%; mean age, 59.3 years)] underwent baseline
brain magnetic resonance imaging (MRI) to visualize CSVD, which included logtransformed white matter hyperintensities (log-WMH) volume and the presence
(yes/no) of lacunes, cerebral microbleeds (CMB), or enlarged perivascular spaces
(EPVS). Linear and logistic regression models were applied to examine the
association between CSVD and each +10-mmHg increment in the office and
ambulatory systolic BP measurements. Improvement in the fit of nested logistic
models was assessed by the log-likelihood ratio and the generalized R2 statistic.
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Results: Office and ambulatory systolic BP measurements were related to log-WMH
(β-correlation coefficients ≥0.08; P < 0.001). Lacunes and CMB were only associated
with ambulatory systolic BP measurements (odds ratios [OR] ranged from 1.31 [95%
confidence interval, 1.10-1.55] to 1.46 [1.17–1.84], P ≤ 0.003). Accounted for daytime
systolic BP, both the 24-h (β-correlation, 0.170) and nighttime (β-correlation, 0.038)
systolic BP measurements remained related to log-WMH. When accounted for 24-h or
daytime systolic BP levels, the nighttime systolic BP retained the significant association
with lacunes (ORs, 1.05–1.06; 95% CIs, ≥1.01 to ≤1.13), whereas the 24-h and
daytime systolic BP levels were not associated with lacunes after adjustments for
nighttime systolic BP (ORs, ≤0.88; 95% CI, ≥0.77 to ≤1.14). On top of covariables
and office systolic BP, ambulatory systolic BP measurements significantly improved
model performance (1.05% ≥ R2 ≤ 3.82%). Compared to 24-h and daytime systolic
BP, nighttime systolic BP had the strongest improvement in the model performance; for
WMH (1.46 vs. 1.05%) and lacunes (3.06 vs. ≤2.05%).
Conclusions: Twenty-four-hour and nighttime systolic BP were the more robust
BP measurements associated with CSVD, but the nighttime systolic BP level had
the strongest association. Controlling ambulatory BP levels might provide additional
improvement in the prevention of CSVD.
Keywords: cerebral small vessel disease, white matter hyperintensities, lacunes, cerebral microbleeds, enlarged
perivascular spaces, ambulatory blood pressure monitoring, nighttime blood pressure

INTRODUCTION

the association of subclinical markers of CSVD with office and
ambulatory BP measurements. We also tested the improvement
of the model performance of ambulatory BP measurements on
top of office BP and conventional risk factors in the prediction
of CSVD.

Cerebral small vessel disease (CSVD) has repeatedly been linked
to poor cognition, increased risk of stroke, and dementia (1, 2).
Arteriolosclerosis or type I CSVD is the most common type
of CSVD and includes white matter hyperintensities (WMH),
lacunes, cerebral microbleeds, and enlarged perivascular spaces
(3). Within the etiological framework of type I CSVD,
hypertension plays an essential role. Numerous studies have
documented that the optimal control of blood pressure (BP)
level significantly reduced the progression of these lesions (4–
6), which, in turn, lowers the risk for adverse health outcomes
associated with aging (7, 8). To monitor BP control through
antihypertensive therapy, adequate measurement of the BP is
imperative (9). Current guidelines recognize that ambulatory
BP monitoring is the state-of-art method to quantify the
BP level compared to office BP measurements (10, 11), and
24-h and nighttime BP levels have the strongest association
with cardiovascular outcomes compared to office and daytime
BP levels (12). Office and ambulatory BP measurements are
individually associated with the presence and development
of CSVD in population-based studies (13–15) and patient
cohorts (16–20). Nevertheless, no studies have been compared,
which BP measurements have the strongest association with
CSVD, especially, for lacunes, cerebral microbleeds, and enlarged
perivascular spaces in the general population (13–15). Moreover,
it remains undocumented whether ambulatory BP measurements
provide additional information for the prediction of CSVD
beyond office BP and conventional risk factors. To address these
issues, we analyzed the Maracaibo Aging Study data to assess
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MATERIALS AND METHODS
Study Cohort
The Maracaibo Aging Study is a prospective populationbased study of community-dwelling individuals ≥40 years
of age from the Santa Lucia (since 1998) and Santa Rosa
de Agua (since 2010) neighborhoods located in the city
of Maracaibo, Venezuela (21). Detailed methodology of the
Maracaibo Aging Study is described elsewhere (21). From
August 2011 until June 2016, 534 participants were additionally
enrolled, using a sampling frame prioritizing the female ancestral
lines with the intention to engage in genetic studies. In
this study phase, participants underwent neurological and
cardiovascular assessments. The Institutional Review Boards
of the Cardiovascular Institute at the University of Zulia,
Maracaibo, and Columbia University, New York, approved the
Maracaibo Aging Study, which complied with the Helsinki
declaration for investigations into human subjects (22). All
participants signed an informed consent form. For this study, we
included participants who had ambulatory BP monitoring with
a minimum number of 15/5 daytime and nighttime ambulatory
BP recordings (10), and MRI scans evaluated between 2011
and 2016.
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Magnetic Resonance Imaging (MRI)

Blood Pressure Measurement

Magnetic resonance imaging (MRI) scans were obtained on
a 1.5-T scanner (GE Healthcare). It included T1-weighted,
T2-weighted, gradient echo, diffusion-weighted imaging,
angiography, and, for the purposes of this study, T2-weighted
fluid-attenuated inversion recovery (FLAIR) scans. The FLAIR
image parameters were TR = 8,000 ms, TE = 123 ms, 2,000 [ms]
inversion time, 25-cm FOV, 2 NEX, 256 × 192 matrix with 2-mm
slice thickness, 0 mm spacing, 63 slices; 6:01; COIL 8NHEAD_A,
and an oblique orientation (axial following commissural plane).
Individuals with a pacemaker, aneurysm clip, neurostimulator,
cochlear implant, or body weight >110 kg were excluded from
MRI scans. The MRI images were transferred to Columbia
University for morphometric analysis.

A nurse or physician measured the office BP with a validated
oscillometric device (Dynamap R ). The office BP was the average
of five consecutive readings in the sitting position. Validated
oscillometric 90207 Spacelabs monitors (Snoqualmie, WA) (26)
were programmed to obtain readings at 15-min intervals from
6 AM until 11 PM, and at 30-min intervals from 11 PM until 6
AM (Supplementary Table 1). The same SAS macro-processed
all ambulatory BP recordings, which stayed unedited, with the
exception of readings with higher diastolic BP than systolic
BP, or flagged with an error code. The within-subject 24-h BP
was a time-weighted average, giving weights to each individual
reading proportional to the time lag with the previous reading.
Hypertension categories based on office and ambulatory BP
measurements were defined according to the ACC/AHA 2017
guidelines (11). Office hypertension was a systolic or diastolic
BP of ≥130/80-mm Hg or use of antihypertensive drugs. 24-h,
daytime, and nighttime hypertension were systolic or diastolic BP
levels of ≥125/75, ≥130/80, and ≥110/65 mm Hg; respectively.
The dipping ratio was calculated by dividing the nighttime by the
daytime BP level (27).

Cerebral Small Vessel Disease
Subclinical CSVD was categorized into quantitative (total WMH)
and qualitative (presence of lacunes, cerebral microbleeds,
and enlarged perivascular spaces) measurements (23). WMH
were automatically quantified as hyperintensities observed on
T2-weighted MRI. The full description of how WMH are
automatically quantified has been published elsewhere (24).
Briefly, each participant’s T2-weighted FLAIR image was brainextracted, and a single Gaussian curve was fit to voxel intensity
values in the brain-extracted image. Intensity values of >2.1
standard deviations (SD) above the whole-brain mean intensity
value were labeled as hyperintense voxels. The threshold was
set by a trained operator who visually inspected the results.
After visual inspection of each image, and correction, if
necessary, the total WMH volume was derived by summing
the number of labeled voxels and multiplying the value by the
voxel dimensions. The WMH volumes were co-registered to
the brain-extracted T1-weighted volumes defined by FreeSurfer
(version 6.0, surfer.nmr.mgh.harvard.edu), and the Euclidean
distance between each WMH-labeled voxel was computed and
accounted for total cranial volume. Lacunes were characterized
as focal lesions of at least 3-mm diameter, with signal intensities
corresponding to liquid (hyperintense on T2-weighted images
and hypointense on FLAIR images). Cerebral microbleeds
were defined as rounded hypointense lesions on T2-weighted
gradient echo-images with a diameter of <10 mm, an additional
visualization on T1-weighted scans for differential diagnosis
against other microvascular lesions. Symmetrical hypointensities
in the globi pallidi, likely representing calcifications, sulcal flow
voids from cortical vessels, and hypointensities, possibly due to
partial volume artifacts from bone, were disregarded. Cerebral
microbleeds were identified as definite microbleeds based on the
Microbleed Anatomical Rating Scale (25), and were classified
as: total microbleeds and, also, based on their localization as
lobar, deep, or mixed cerebral microbleeds. Enlarged perivascular
or Virchow-Robin spaces were defined as round, oval, or linearshaped lesions with a diameter of >5 mm, with a smooth margin,
absence of mass effect, and with a signal intensity equal to
interstitial fluid on T2-weighted images, with a flair rim around
them, and (if visible) hypointense on FLAIR images without a
hyperintense rim to distinguish them from old lacunar infarcts.
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Demographic and Clinical Characteristics
We documented demographic and clinical information related
to CSVD, and this was collected by physicians and trained
nurses. The observers administrated questionnaires to collect
each participant’s medical history: smoking status, drinking
habits, use of antihypertensive or antidiabetic medications, and
educational attainment. History of smoking included past and
current smoking. Obesity was defined as a body mass index
(BMI) of ≥30 kg/m2 . Diabetes mellitus was defined based on the
criteria of the Seventh Report of the Joint National Committee
(28) as a glucose serum level of ≥126 mg/dL or intake of
anti-diabetic drugs. The glomerular filtration rate was estimated
according to the method of the National Institute of Diabetes
and Digestive and Kidney Disease (29). History of cardiovascular
disease included ischemic coronary diseases, heart failure, or
stroke prior to the MRI and BP assessments.

Statistical Analyses
We compared means by t-tests or Wilcoxon-Mann-Whitney,
and proportions by Fisher exact test. Due to a non-parametric
distribution, we log-transformed total WMH (log-WMH)
volume to conduct regression analyses and expressed associations
as per +1 SD increment in the log-WMH. After stratification
for sex, we interpolated missing values of BMI (n = 5), total
serum cholesterol (n = 56), low-density (n = 79), and highdensity serum cholesterol (n = 79), and serum creatinine (n =
60) from the regression slopes on age. We selected covariables
based on their pathological role with CSVD (sex, age, BMI,
diabetes mellitus, use of antihypertensive treatment, glomerular
filtration rate, high-density serum cholesterol, and history of
cardiovascular diseases) or potential confounders (education
and cephalic circumference). We expressed odds ratios (for
lacunes, cerebral microbleeds, and enlarged perivascular spaces)
and correlation coefficients (for log-WMH) per +10/5-mm
Hg increment in the systolic/diastolic BP, and per +0.10-mm
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Hg increment in the systolic dipping ratio. We estimated the
probability of having CSVD according to categories of office, 24h, daytime, and nighttime systolic BP (normal BP, elevated BP,
stage-1, stage-2, and severe hypertension). The probability was
derived from logistic regression models that accounted for the
selected confounders, and heatmaps were constructed to visualize
the contribution of each category to the probability of having
CSVD. To estimate the probability for WMH, we had to divide
log-WMH into normal (<90th of the percentile distribution) and
high (≥90th) WMH.
To determine which office or ambulatory BP measurements
were better associated with CSVD, we simultaneously included
two BP measurements in the same model (e.g., 24-h and
daytime BP). Because of the collinearity effect, we applied the
residuals method to uncorrelated ambulatory BP measurements
by regressing one measurement on the other. For example,
when assessing whether nighttime BP was better associated
with CSVD than 24-h BP, we regressed nighttime BP on 24h BP and used the residuals to compute side effects (beta
coefficients, odds ratios) while adjusting the model by 24-h BP.
Improvement in the fit of nested logistic models was assessed
by the log-likelihood ratio and the generalized R2 statistic.
In sensitivity analyzes, we associated CSVD with office and
ambulatory diastolic BP measurements, and we also conducted
analyzes by excluding participants with previous strokes to
ensure that the association between ambulatory BP levels and
CSVD was not driven by the presence of stroke. A two-tailed αlevel of ≤0.05 was deemed statistically significant. For database
management and statistical analysis, we used SAS software,
version 9.4, maintenance level five.

TABLE 1 | Baseline characteristics of the Maracaibo Aging Study participants with
brain MRI data.
Characteristics

Whole sample (n = 429)

No of participants — no. (%)
Women — no. (%)

316 (73.7)

Smoking — no. (%)

123 (28.7)

Drinking alcohol — no. (%)

187 (45.1)

Obesity — no. (%)

139 (32.4)

Diabetes mellitus — no. (%)

70 (16.3)

Previous history of CV diseases — no. (%)

32 (7.5)

Previous stroke — no. (%)

11 (2.6)

Office hypertension — no. (%)

289 (67.4)

24-H hypertension — no. (%)

195 (45.4)

Daytime hypertension — no. (%)

150 (35.0)

Nighttime hypertension — no. (%)

292 (68.1)

On antihypertensive treatment — no. (%)

145 (33.8)

Cerebral small vessel disease — no. (%)
Lacunes

38 (8.9)

Cerebral microbleeds*

51 (11.9)

Lobar microbleeds

25 (6.2)

Deep microbleeds

30 (7.4)

Mixed microbleeds

8 (2.1)

Enlarged perivascular spaces

32 (7.5)

Mean (±SD) median (IQR) with characteristic
Age — y
Education — y

59.3 ± 13.0
†

6 (3–11)

Body mass index — kg/m2

RESULTS

28.0 ± 5.5

Cephalic circumference — cm

55.1 ± 1.9

Serum fasting glucose, mg/dL

108.4 ± 37.6

Total serum cholesterol — mg/dL

197.8 ± 44.9

High-density lipoprotein serum cholesterol — mg/dL

44.7 ± 11.9

Baseline Characteristics

Low-density lipoprotein serum cholesterol — mg/dL

127.5 ± 37.2

The study population had a mean age of 59.3 (range, 5th95th percentile interval, 49–70 years) and included 73.7%
(n = 316) women (Table 1). Among 429 participants, onethird were smokers (28.7%), had obesity (32.4%), or were
on antihypertensive treatment (n = 33.8%). The prevalence
of diabetes mellitus, history of cardiovascular diseases, and
stroke was 16.3, 7.5, and 2.6%, respectively. Almost half of the
participants had an office (67.4%) or a 24-h (45.4%) hypertension,
whereas the prevalence of daytime and nighttime hypertension
was 35 and 68.1%, respectively. In addition, we reported 8.9% (n
= 38) participants with lacunes, 11.9% (n = 51) with cerebral
microbleeds, and 7.46% (n = 32) with enlarged perivascular
spaces were detected (Table 1).

Serum triglycerides — mg/dL

†

Office systolic/diastolic BP— mm Hg

79.4 ± 22.8
140.1 ± 24.6/77.7 ± 11.0

24-h systolic/diastolic BP — mm Hg

121.6 ± 15.3/71.8 ± 9.2

Daytime systolic/diastolic BP — mm Hg

123.5 ± 14.6/73.7 ± 9.1

Night-time systolic/diastolic BP — mm Hg

116.8 ± 17.5/67.2 ± 10.7

White matter hyperintensities — cm3

2.63 (1.80–4.05)

SD, standard deviation; IQR, interquartile range; BP, blood pressure.
*Three cerebral microbleeds were infratentorial (brainstem and cerebellum).
†

Years of education and serum triacylglycerides were presented as interquartile range as
measure of spread.

daytime, and nighttime systolic BP (β coefficients between 0.12
and 0.14; 95% CI, ≥08 ≤0.19, P < 0.001). The odds ratios (ORs)
for lacunes and cerebral microbleeds per +10-mm Hg increment
in the 24-h, daytime, and nighttime systolic BP ranged between
1.31 (95% CI, 1.10–1.55; P = 0.002) and 1.47 (95% 1.21–1.79;
P < 0.001). Based on the locations of the cerebral microbleeds
(Supplementary Table 2), office systolic BP was only associated
with mixed microbleeds (OR, 1.79; 95% CI, 1.17–2.73; P = 0.006);
whereas, the presence of lobar or deep cerebral microbleeds was
significantly associated with 24-h, daytime, and nighttime systolic

Cerebral Small Vessel Disease and Blood
Pressure Measurements
In univariate regression analyses (Table 2), the office and
ambulatory BP measurements were all significantly associated
with CSVD (P ≤ 0.041). In adjusted regression models (Table 2),
each +10-mm Hg increment in the office systolic was associated
with larger total log-WMH (β correlation coefficient per +1-SD
larger log-WMH = 0.08; 95% confidence interval [CI], 0.05-0.12;
P < 0.001). Similarly, the associations were retained for the 24-h,

Frontiers in Neurology | www.frontiersin.org

131 (89–173)

Glomerular filtration rate — mL/min per 1.73m2
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TABLE 2 | Association of quantitative and categorical subclinical markers of cerebral small vessel disease with office and ambulatory blood pressure measurements.
BP measurements

Total Log-WMHs

Lacunes

Cerebral microbleeds

Enlarged perivascular

(per 1-SD increase)

(n = 38)

(n = 51)

spaces (n = 18)

β coefficient (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

Office systolic BP

0.13 (0.10, 0.16)

<0.001

1.27 (1.13–1.44)

<0.001

24-H systolic BP

0.21 (0.16, 0.26)

<0.001

1.54 (1.27–1.87)

<0.001

1.19 (1.07–1.33)

0.002

1.16 (1.02–1.33)

0.024

1.44 (1.20–1.71)

<0.001

1.29 (1.05–1.60)

Daytime systolic BP

0.20 (0.15, 0.26)

<0.001

1.52 (1.24–1.90)

0.016

<0.001

1.45 (1.20–1.74)

<0.001

1.33 (1.07–1.65)

Nighttime systolic BP

0.18 (0.14, 0.22)

<0.001

1.52 (1.28–1.80)

0.011

<0.001

1.36 (1.16–1.58)

<0.001

1.21 (1.01–1.45)

0.041

Unadjusted models

Adjusted models
Office systolic BP

0.08 (0.05, 0.12)

<0.001

1.14 (0.98–1.33)

0.09

1.13 (0.98–1.29)

0.08

1.14 (0.97–1.35)

0.11

24-H systolic BP

0.14 (0.09, 0.19)

<0.001

1.46 (1.17–1.84)

<0.001

1.39 (1.14–1.70)

0.001

1.27 (0.99–1.62)

0.050

Daytime systolic BP

0.13 (0.08, 0.19)

<0.001

1.42 (1.13–1.80)

0.003

1.40 (1.14–1.72)

0.002

1.30 (1.01–1.70)

0.038

Nighttime systolic BP

0.12 (0.07, 0.16)

<0.001

1.47 (1.21–1.79)

<0.001

1.31 (1.10–1.55)

0.002

1.19 (0.96–1.48)

0.11

OR, odds ratio; CI, confidence interval; BP, blood pressure; WMH, white matter hyperintensities.
β coefficients and odds ratios are given by each +10-mm Hg increase in the systolic BP. Adjusted models accounted sex, age, education, cephalic circumference, body mass index,
diabetes mellitus, high-density serum cholesterol, use of antihypertensive treatment, glomerular filtration rate, and previous history of cardiovascular diseases. The association of cerebral
microbleeds according to its location (lobar, deep, or mixed) is shown in Supplementary Table 2.

BP were not associated after adjustments for nighttime systolic
BP. No association between ambulatory BP measurements and
cerebral microbleeds (Table 3 and Supplementary Table 6), or
enlarged perivascular spaces, (Table 3) were observed when these
BP measurements were simultaneously included in the same
logistic regression models (ORs ratios ranged from 0.96 to 1.10;
95% CI ranged from 0.84 to 1.23; P ≥ 0.17). After accounting
for ambulatory 24-h or nighttime systolic BP measurements,
the systolic dipping ratio was not associated with CSVD
(Supplementary Table 7, P ≥ 0.18).

BP (OR ≥ 1.30; 95% CI ranged from 1.04 to ≤4.31; P ≤ 0.022).
Every +5-mm Hg increment on the level of ambulatory diastolic
BP measurements was significantly associated with larger logWMH [β correlation coefficient ≥0.05; 95% CI, ≥0.01 to
≤0.10; P ≤ 0.033 (Supplementary Table 3)], and the presence of
enlarged perivascular spaces [ORs ranged between 1.22 and 1.36;
95% CI, ≥1.02 to ≤1.70; P ≤ 0.030 (Supplementary Table 3)].
Our findings were consistent after excluding the participants with
history of stroke (Supplementary Table 4).
The probability of having a high volume of WMH and lacunes
increased with nighttime systolic BP categories, ranging from
0.73–3.70% (normal BP, <100 mm Hg) to 10.8-15.3% (severe
hypertension, ≥140 mm Hg), respectively (Figure 1). For these
same categories, the probability according to office systolic BP
categories ranged from 1.18 to 7.63%, and 4.53 to 9.15%. Similar
trends were observed between ambulatory BP categories and
other markers of CSVD.

Model Performance
The basic model accounted for sex, age, education, cephalic
circumference, BMI, diabetes mellitus, use of antihypertensive
treatment, glomerular filtration rate, and history of
cardiovascular diseases (Table 4). On top of the basic model,
office systolic BP significantly improved model performance
for top-90th log-transformed WMH (R2 = 5.02%; P < 0.001),
but not for lacunes, enlarged perivascular spaces, or cerebral
microbleeds. In contrast, the inclusion of ambulatory systolic
BP measurements on top of basic models and office systolic BP
resulted in significant improvement of the model performance
for top-90th log-WMH, lacunes, and cerebral microbleeds (R2
ranged from 0.97 to 3.09%; P ≥ 0.072).

Comparison of Blood Pressure
Measurements
When adjusted for 24-h ambulatory BP measurements, the
office systolic BP lost significance relationship with log-WMH
(Supplementary Table 5; P ≥ 0.053). The ambulatory systolic
BP measurements remained associated with log-WMH after
adjustment for office BP (Supplementary Table 5; P ≤ 0.006).
Adjustment for daytime systolic BP did not remove the statistical
significance of 24-h and nighttime systolic BP in relation to
total WMH (P ≤ 0.023), whereas the significance of higher
daytime systolic BP level did not remain after adjustment for
24-h or nighttime systolic BP levels (Figure 2). For lacunes
Table 3, nighttime systolic BP level retained the significance after
accounted for 24-h or daytime systolic BP (ORs between 1.05
and 1.06; 95% CI ranged between ≥1.01 and ≤1.10; P ≤ 0.036).
However, the 24-h (OR, 0.97; 95% CI, 0.91-1.04; P = 0.46)
and daytime (OR, 0.88; 95% CI, 0.77–1.02; P = 0.09) systolic

Frontiers in Neurology | www.frontiersin.org

DISCUSSION
In this population-based study, higher 24-h and nighttime
systolic BPs, compared with office and daytime BP
measurements, were better associated with a larger accumulation
of WMH volume and a higher probability of having lacunes or
cerebral microbleeds. The daytime BP, rather than nighttime
BP, was better associated with enlarged perivascular spaces.
The probability (%) of high burden of WMH volume and
lacunes were higher across nighttime systolic BP categories
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FIGURE 1 | Heat maps displaying the probability (%) of having subclinical markers of cerebral small vessel disease according to office and ambulatory blood pressure
Categories. BP indicates blood pressure; WMH, white matter hyperintensities; HT, hypertension. Normal, elevated BP, stage-1, stage-2, and severe hypertensions
thresholds were 120/130/140/160 mm Hg for office systolic BP, 115/125/130/145 for 24-h, 120/130/135/145 for daytime, and 100/110/120/140 for nighttime BP.
Numbers inside the box indicates the probability of having top-90th total log-WMH (A), lacunes (B), cerebral microbleeds (C), or enlarged perivascular spaces (D).
The probability was derived by multivariable logistic regression and was standardized to the average of the distributions in the whole study population of sex, age,
education, cephalic circumference, body mass index, diabetes mellitus, use of antihypertensive treatment, glomerular treatment, and history of cardiovascular
diseases.

compared to other BP measurements, with corresponding rates
of 0.73–15.3% between normal systolic BP and severe systolic
hypertension. In adjusted regression models, office systolic
BP was only related with total WMH volume. However, this
association did not remain significant after accounting for
ambulatory BP measurements. Our findings were consistent in
participants stroke-free history. The model performance was
significantly improved by 24-h and nighttime systolic BP levels
on top of conventional risk factors and office systolic BP from
0.69 to 3.06%.
Being consistent with previous publications, the prevalence
of cerebral microbleeds, lacunes, and enlarged perivascular
spaces was 11.9, 8.9, and 7.5%, respectively (13, 30). In
comparison to other Hispanic participants residing in or
outside of the United States, our prevalence is comparable.s

Frontiers in Neurology | www.frontiersin.org

In the Northern Manhattan Study, constituted by ∼60–70%
of Hispanic participants from the general population, the
prevalence of lacunes and cerebral microbleeds was 13.4 and
4.92%, respectively (13, 31). Similarly, in a Mexican-American
cohort, the prevalence of lacunes and cerebral microbleeds was
4.3 and 10.3%, respectively (32). In addition, in the Atahualpa
Project, which is a population-based study of older adults living
in rural areas of Ecuador, the rate of lacunes and cerebral
microbleeds was 14.7 and 14%, respectively (33). Of note, the
distribution of deep, lobar, and mixed cerebral microbleeds was
also similar in our study compared to those cohorts of Hispanics
participants from the general population.
Numerous studies documented that nighttime BP carries the
most valuable prognostic information in relation to adverse
health outcomes (12, 34–36). In line with these studies, we
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FIGURE 2 | Association between total log-transformed white matter hyperintensities and standardized ambulatory systolic blood pressure measurements. The
ambulatory blood pressure (BP) measurements were all standardized by sex, age, education, cephalic circumference, body mass index (BMI), diabetes mellitus,
high-density serum cholesterol, use of antihypertensive treatment, glomerular filtration rate, and history of cardiovascular diseases. The 24-h systolic BP was
additionally adjusted for daytime (A) and nighttime (B) systolic BP levels. The daytime systolic BP was additionally adjusted for 24-h (C) and nighttime (D) systolic BP
levels. Finally, the nighttime systolic BP was additionally adjusted for 24-h (E) and daytime (F) systolic BP levels.

TABLE 3 | Association between categorical subclinical markers of cerebral small vessel disease and ambulatory systolic blood pressure measurements.
Quantitative markers of
cerebral small vessel
disease

Adjusted for

Adjusted for

Adjusted for

24-h systolic BP

daytime systolic BP

nighttime systolic BP

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

Lacunes (n = 38)
NA

NA

1.16 (1.02–1.33)

0.026

0.97 (0.91–1.04)

0.40

Daytime systolic BP

24-H systolic BP

0.88 (0.77–1.02)

0.09

NA

NA

0.98 (0.94–1.03)

0.47

Nighttime systolic BP

1.06 (1.01–1.13)

0.036

1.05 (1.01–1.10)

0.001

NA

NA

Cerebral microbleeds (n = 51)
24-H systolic BP

NA

NA

1.04 (0.92–1.16)

0.56

1.03 (0.97–1.09)

0.33

Daytime systolic BP

0.99 (0.88–1.13)

0.97

NA

NA

1.02 (0.98–1.07)

0.32

Nighttime systolic BP

1.01 (0.95–1.06)

0.91

1.01 (0.98–1.05)

0.53

NA

NA

Enlarged perivascular spaces (n = 18)
24-H systolic BP

NA

NAA

0.96 (0.84–1.11)

0.60

1.04 (0.97–1.12)

0.20

Daytime systolic BP

1.07 (0.92–1.23)

0.38

NA

NA

1.03 (0.98–1.09)

0.17

Nighttime systolic BP

0.98 (0.93–1.04)

0.54

0.99 (0.95–1.04)

0.73

NA

NA

OR, odds ratio; BP, blood pressure; WMH, white matter hyperintensities; NA, no applicable. OR are given by mm Hg unit increase in the systolic BP. Models accounted sex, age,
education, cephalic circumference, body mass index, diabetes mellitus, high-density serum cholesterol, use of antihypertensive treatment, glomerular filtration rate, and previous history
of cardiovascular diseases. Models including 2 correlated systolic BP measurements were constructed, using the residual method (see statistical analysis section). Office systolic BP
did not remain associated with log-transformed total WMH after adjustment for 24-h systolic BP (P = 0.053, see Supplementary Table 6).
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TABLE 4 | Nested fit of logistic models relating quantitative and categorical subclinical markers of cerebral small vessel disease and blood pressure measurements.
Models

χ2 statistic

P

R2 (%)†

Top-90th log-transformed-WMH (no/yes)
Base model*

64.3

<0.001

15.2

+ Office systolic BP

80.3

<0.001

4.00

+ Office systolic BP + 24-h systolic BP

84.4

0.042

1.05

+ Office systolic BP + Daytime systolic BP

83.0

0.098

0.69

+ Office systolic BP + Nighttime systolic BP

86.0

0.016

1.46

+ Office systolic BP + Ambulatory BP measurements

88.6

0.004

2.10

Lacunes (no/yes)
Base model*

25.3

<0.001

6.27

+ Office systolic BP

28.5

0.074

0.81

+ Office systolic BP + 24-h systolic BP

36.6

0.004

2.05

+ Office systolic BP + Daytime systolic BP

34.4

0.015

1.50

+ Office systolic BP + Nighttime systolic BP

40.7

<0.001

3.06

+ Office systolic BP + Ambulatory BP measurements

43.8

<0.001

3.82

Cerebral microbleeds (no/yes)
Base model*

16.5

<0.001

4.12

+ Office systolic BP

19.7

0.072

0.82

+ Office systolic BP + 24-h systolic BP

26.9

0.007

1.83

+ Office systolic BP + Daytime systolic BP

26.6

0.008

1.74

+ Office systolic BP + Nighttime systolic BP

25.9

0.012

1.59

+ Office systolic BP + Ambulatory BP measurements

27.0

0.007

1.86

Enlarged perivascular spaces (no/yes)
Base model*

9.7

0.002

2.45

+ Office systolic BP

12.1

0.119

0.62

+ Office systolic BP + 24-h systolic BP

13.6

0.222

0.38

+ Office systolic BP + Daytime systolic BP

14.0

0.167

0.48

+ Office systolic BP + Nighttime systolic BP

12.8

0.405

0.18

+ Office systolic BP + Ambulatory BP measurements

15.7

0.057

0.92

WMH denotes white matter hyperintensities, BP, blood pressure. On top of 24-h or nighttime systolic BP, office systolic BP only improved the model performance for top-90th logtransformed WMH (R2 from 1.02 to 1.14%; P = 0.045 and P = 0.034). When basic model additionally accounted for all the ambulatory systolic BP measurements, office systolic BP
did not longer improve model performance (P = 0.074).
*Basic models accounted for sex, age, education, cephalic circumference, body mass index, diabetes mellitus, high-density serum cholesterol, use of antihypertensive treatment,
glomerular filtration rate, and history of cardiovascular diseases.
† R2 is an estimate of the additional variance explained (https://apha.confex.com/apha/134am/techprogram/paper_135906.htm).

sodium excretion, nocturnal pressure natriuresis, impaired
endothelial function, or all (38). Individuals with nocturnal
hypertension usually suffer from comorbidities, such as diabetes,
dyslipidemia, or obesity, which substantially increase their
cardiovascular risk. Patients at high-risk would benefit from
antihypertensive therapy guided by ambulatory BP monitoring.
The role of hypertension in the presence and development
of CSVD is irrefutable. High office BP relates to CSVD.
Considering our findings, nocturnal hypertension might have
a greater impact on the brain microcirculation, predisposing
to a higher extent the presence of CSVD. Therefore, it is
important to describe the physiopathological changes in the
cerebral microcirculation associated with hypertension. Based
on its etiology, CSVD can be classified into arteriolosclerosis,
cerebral amyloid angiopathy, inherited or genetic, inflammatory
and immune-mediated, venous collagenosis, and others (3).
The most common types are arteriolosclerosis (or type

also observed that 24-h and nighttime systolic BP showed the
strongest association with CSVD. Of note, the role of 24-h
systolic BP might be driven by nighttime BP levels due to the
high prevalence of nighttime hypertension (68.1%), which can
be explained by the change on the ORs of the 24-h systolic BP
from above 1 unit to below 1 unit when accounted for nighttime
BP levels. The mechanisms involved in the association between
CSVD and nighttime BP might be (i) uncontrolled nocturnal
hypertension due to lack of antihypertensive therapy during the
nighttime (37), or (ii) inherent pathophysiological mechanisms
that increase the nighttime BP (38). Antihypertensive therapy
is a major confounder when ambulatory BP is examined as
the medication is usually taken during the daytime, making it
plausible that the BP-lowering effect of the drugs decreases or
wean off at night (37). On the other hand, nocturnal hypertension
might result from sympathetic modulation of the nighttime BP,
disturbed baroreflex sensitivity, sleep apnea, decreased daytime
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compared to patients at low risk (42). Documenting the absolute
risk for CSVD based on BP levels, as well as other risk factors,
might guide the decision making process to determine which
patients should undergo further cardiovascular assessments.
Daytime BP seemed to be the strongest BP index associated
with enlarged perivascular spaces, which agrees with the two
previously published studies available in the current literature
in patients with stroke (18, 43). We hypothesized that the two
mechanisms might explain such association. First, the response
of cerebral autoregulatory mechanisms to BP. A surge of the BP
beyond the cerebral autoregulatory capacity induces dilatation of
cerebral vessels and leads to changes in the permeability of the
blood-brain barrier (44, 45). Because daytime BP is higher than
nighttime BP, the autoregulatory capacity of the cerebral vessels
would be more likely exceeded during the daytime. Subsequent
changes in the permeability allow fluid to leaks out and overload
in the perivascular space (44). Second, the physiological changes
of the amount of fluid within the perivascular spaces throughout
the day (46) can be exacerbated by higher daytime BP. These
hypothetical mechanisms need to be validated, and longitudinal
data are needed to determine whether controlling ambulatory BP
level will result in lower perivascular spaces.

I) and cerebral amyloid angiopathy (type II), but type
I pertains to vascular risk factors commonly associated
with aging such as hypertension. The physiopathological
vascular changes associated with arteriolosclerosis include
fibrinoid necrosis, microaneurysm, hyalinosis, fibrohyalinosis,
microatheroma, lipohyalinosis, atherosclerosis, and segmental
arterial disorganization. These pathological findings define the
functional and structural changes of small arteries associated
with hypertension. Therefore, by understanding the possible
etiologies in CSVD, the identification of risk factors potentially
leads to better diagnostic and preventive strategies. This is
clinically valuable as hypertension, which is the main risk factor
for arteriolosclerosis CSVD, is a preventable modifiable risk
factor and yet, it remains the first cause of cardiovascular
and cerebrovascular complications worldwide due to the poor
diagnosis, treatment, and control rates (9).
The clinical implications of our study rely on the management
of nocturnal hypertension for prevention of CSVD. Given
the compelling evidence, hypertension guidelines indicated
ambulatory BP monitoring as the state-of-art method to measure
BP level (10, 11). Yet, substituting office for ambulatory BP
measures in clinical settings remains controversial. CSVD is
considered as a subclinical marker of target-organ damage, and
based on The Lancet Commissions (9), controlling BP is the
second avoidable level in the prevention of major cardiovascular
events, and loss of quality of life, especially in advanced age.
With CSVD being a common result of hypertension-related
arteriolosclerosis (3), antihypertensive therapy should be guided
by both office and ambulatory BP measures, and should be aimed
at nighttime normotension. To date, the superiority of bedtime
vs. daytime therapy to control BP remains unclear and only one
study has addressed such superiority–the Hygia Chronotherapy
Trial (39). The study showed that bedtime medication, as
opposed to upon waking, improved ambulatory BP control and
diminished the risk of major cardiovascular events by 45%.
The findings from the Hygia study should be interpreted with
caution as its findings remains under debate (40, 41). Until now,
the guidelines do not propose nighttime BP treatment as the
main therapy target but aiming at daytime and nighttime BP
normotension seems reasonable.
No studies have documented the absolute risk of CSVD
according to ambulatory BP categories. Due to the cross-sectional
design of our study, we were unable to assess absolute risk.
However, the probability (%) derived from adjusted logistic
regression modeling may put our findings in perspective. As an
example, for the same ambulatory hypertension categories, the
probability of having a high accumulation of WMH, lacunes,
or cerebral microbleeds was higher than the corresponding
office hypertension categories – between 3 and 10%. This
information is clinically relevant as current international
hypertension guidelines recommend treatment for hypertension
based on an absolute risk of cardiovascular diseases (e.g., the
Framingham Risk Score) (9). Moreover, the absolute risk also
influences the decision-making in treating high-risk individuals
as demonstrated by the Systolic blood pressure intervention trial
(SPRINT) study, where individuals with a higher cardiovascular
risk had more benefits with intense antihypertensive treatment
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Strengths and Limitations
The strengths of our study included the comprehensive
information on cardiovascular risk factors, the availability
of assessment for ambulatory BP and MRI scans at the
same time point, consideration of multicollinearity among
BP measurements by applying the residual method, and
the separate analyses of subclinical markers of CSVD. The
predictive value of nighttime systolic BP was replicable in three
outcomes (WMH, lacunes, and cerebral microbleeds), further
strengthening our hypothesis. Nevertheless, the present study
should be interpreted within the context of its limitations. First,
the cross-sectional design prevented causal inferences. Although
we were unable to assess the predictive power of ambulatory
BP measurements, numerous studies have documented that
ambulatory BP measurements predicted the development and/or
progression of cerebral small vessel disease (6, 16, 47). Second,
we did not record the BP diary and, therefore, we were unable
to adequately address the role of antihypertensive treatment
in the association between cerebral small vessel disease and
ambulatory BP measurements. Third, the generalizability of
these findings is limited to the general population, especially
because of the overrepresentation of women in the MAS. Lastly,
detection of subclinical markers of CSVD strongly depends on
MRI characteristics and the detection criteria used.

CONCLUSIONS
Our study demonstrated that ambulatory BP measurements
were associated with subclinical markers of CSVD, and
such association was superior to office BP measurements.
Nighttime systolic BP was the strongest BP measurement
associated with WMH, as well as with lacunes. Nevertheless,
we observed that the presence of enlarged perivascular
spaces was better related to daytime BP than any other
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BP measurements. The 24-h ambulatory BP monitoring
may identify individuals who are at high risk of major
cerebrovascular outcomes. In view of the widely available
antihypertensive therapy, physicians should focus on controlling
ambulatory BP, especially in high-risk individuals (e.g., elderly
patients, subjects with history of cardiovascular disease, or
with high burden of cardiovascular risk factors). By preventing
progression of brain target-organ damage, the risk of major
cerebrovascular disease would be substantially reduced, which
improves the quality of life and reduces the disability-adjusted
life years lost.
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